FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1182-1183 October 19, 2000 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Chan, T. M. PubMed Citation

Until the pathogenesis of nephritis due to systemic lupus erythematosus has been unraveled, optimal treatment for patients with this disease will remain an elusive goal. When the causes of lupus nephritis become known, we should be able to design specific immunosuppressive and immunomodulating therapy. Genetic and environmental risk factors may be useful for identifying patients at risk and possibly preventing the development of nephritis. Optimal treatment would include reprogramming B- and T-cell immune responses to ignore nephritogenic antigens, thereby eliminating the elaboration of injurious inflammatory mediators and growth factors and promoting healing.

Patients with systemic lupus erythematosus often have inflammatory . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Glassock, R. J. (2008). Multitarget Therapy of Lupus Nephritis: Base Hit or Home Run?. J. Am. Soc. Nephrol. 19: 1842-1844 [Full Text]  
• Doria, A, Iaccarino, L, Arienti, S, Rampudda, M E, Canova, M G, Rondinone, R, Todesco, S (2006). Mycophenolate mofetil and systemic lupus erythematosus. Lupus 15: 44-54 [Abstract]  
• Ginzler, E M, Aranow, C (2005). Mycophenolate mofetil in lupus nephritis. Lupus 14: 59-64 [Abstract]  
• Somers, M. J., Daouk, G. H., McCluskey, R. T. (2004). Case 11-2004 - A Boy with Rash, Edema, and Hypertension. NEJM 350: 1550-1559 [Full Text]  
• Zabaleta-Lanz, M, Vargas-Arenas, R E, Tapanes, F, Daboin, I, Pinto, J A., Bianco, N E (2003). Silent nephritis in systemic lupus erythematosus. Lupus 12: 26-30 [Abstract]  
• Nachman, P. H., Martin, J. (2002). Developments in the Immunotherapy of Glomerular Disease. Journal of Pharmacy Practice 15: 472-489 [Abstract]  
• Karim, M. Y., Alba, P., Cuadrado, M.-J., Abbs, I. C., D'Cruz, D. P., Khamashta, M. A., Hughes, G. R. V. (2002). Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 41: 876-882 [Abstract] [Full Text]  
• Takada, K, Illei, G G, Boumpas, D T (2001). Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10: 154-161 [Abstract]